Annual Meeting of SIN/SNO Lombardia

Neurological Sciences

, Volume 29, Issue 2, pp 277-278

First online:

Renin-angiotensin system and stroke

  • Simona MarcheselliAffiliated withNeurologia I e Stroke Unit, IRCCS Istituto Clinico Humanitas
  • , Giuseppe MicieliAffiliated withNeurologia I e Stroke Unit, IRCCS Istituto Clinico Humanitas Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The renin-angiotensin system (RAS) is a major regulatory system of cardiovascular and renal function. Many new aspects of this system have been revealed in recent years, leading to new therapeutic approaches. It’s well known that RAS blocking agents have potent antiatherosclerotic effects, which are mediated by their antihypertensive, anti-inflammatory, antiproliferative, and oxidative stress lowering properties. Inhibitors of RAS are now first-line treatments for hypertensive target organ damage. Their effects are greater than expected by their ability to lower blood pressure. Angiotensin receptor blockers reduce the frequency of atrial fibrillation and stroke, are also able to prevent cardiovascular and renal events in diabetic patients. Thus, blockade of RAS represents one of the most important strategies in order to reduce cardiovascular risk.


Angiotensin Stroke ACE-inhibitor Angiotensin II type 1 receptors blocking agent